September 23, 2025

Pfizer to Acquire Obesity Startup Metsera for $4.9 Billion

News Summary

Pfizer Inc. has agreed to acquire Metsera, an obesity startup, for approximately $4.9 billion to enhance its weight-loss drug portfolio. The deal includes an initial cash payment of $47.50 per share, with potential additional payments based on clinical milestones. Following the announcement, Metsera’s shares soared by 58%, while Pfizer’s stock rose by 2.3%. The move is part of Pfizer’s strategy as the obesity drug market is expected to reach $100 billion by 2030, following setbacks in its own obesity drug development.

New York City – Pfizer Inc. has announced its agreement to acquire the obesity startup Metsera for approximately $4.9 billion as part of its strategy to boost its weight-loss drug pipeline. The acquisition deal includes an initial payment of $47.50 in cash per share, representing a 43% premium over Metsera’s closing share price of $33.32 before the announcement. Additionally, there are contingent payments that could total up to $22.50 per share, dependent on Metsera achieving specific clinical and regulatory milestones.

In the wake of this announcement, Metsera’s shares surged by 58% in premarket trading, while Pfizer’s stock increased by 2.3%. This acquisition comes on the heels of Pfizer’s discontinuation of its own weight-loss pill development, which was halted in April due to safety concerns. The move highlights Pfizer’s renewed interest in the rapidly growing obesity treatment market, where competition among pharmaceutical companies is escalating.

Market Outlook and Development Pipeline

The obesity drug market is projected to hit $100 billion by 2030, making it an attractive sector for pharmaceutical investments. Metsera is currently developing a variety of experimental weight-loss drugs, including MET-233i, which has shown potential in helping patients lose up to 8.4% of their body weight in a 36-day study. Despite these promising results, MET-233i remains in the early stages of development and is not expected to be available to patients for several years.

Metsera’s portfolio also offers both injectable and oral treatment options, such as a long-acting amylin analogue designed to provide a gentler alternative to existing GLP-1 drugs. Analysts believe that the obesity drugs in Metsera’s pipeline could generate over $5 billion in combined peak annual sales, depicting a lucrative future for the acquired startup.

Strategic Significance for Pfizer

Pfizer’s CEO, Albert Bourla, stated that acquiring Metsera aligns with the company’s goal of investing in impactful opportunities within the expanding obesity treatment market. This acquisition is critical for Pfizer, which has faced considerable challenges in product development in the obesity category. The company is under significant pressure to replenish its medicine pipeline following the termination of its lead obesity drug candidate, danuglipron, earlier this year due to safety issues.

Regulatory Considerations and Future Steps

The acquisition is subject to approval from Metsera’s shareholders and requires regulatory clearance. The deal is expected to close in the fourth quarter of this year, allowing Pfizer to further solidify its position in the obesity treatment landscape.

Background on Metsera

Founded in 2022, Metsera went public earlier this year and has experienced significant stock appreciation amid a growing interest in obesity treatments. With Pfizer’s substantial investment, Metsera’s future endeavors in weight-loss drug development now hold even greater potential.

This strategic acquisition not only allows Pfizer to enhance its portfolio but also marks a significant step in the competition for dominance in the lucrative obesity drug market.